All In Biotech

Drug Trial Radar · NCT04993729

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

A Multicenter, Double-blind, Randomized and Placebo-controlled Pivotal Phase 3 Study to Evaluate the Safety and Efficacy of T89 in the Prevention and Treatment of Acute Mountain Sickness (AMS) After Rapid Ascent

Last checked: Nov 19, 2026Latest source record: Aug 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". Randomized with 853 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

853

Actual

Start

Jul 21, 2021

Primary completion

May 26, 2023

Study completion May 26, 2023

Sponsor

Lead sponsor
Tasly Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The specific aim of this double blind, randomized phase III trial is to evaluate the safety and efficacy of T89 in preventing Acute Mountain Sickness (AMS) and relieving the symptoms of AMS after rapid ascent.

Conditions

  • Acute Mountain Sickness (AMS)

Interventions

  • T89 capsuleDrug

    T89 capsule (trade name Dantonic®) is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. T89 capsules, p.o. TID.

  • Placebo capsuleDrug

    Placebo capsules, p.o. TID.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of baseline corrected mean LLSS score on Day 4 morning (next mornings after arrival at high altitude) between T89 and placebo groups.Time frame: Baseline and day 4

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Hypoxia Research Lab, UCSF Parnassus Campus, S-256

    San Francisco, California

  • Affiliated Hospital of Chengdu University of TCM

    Chengdu, Sichuan, China

  • Tibet Autonomous Region People's Hospital

    Lhasa, Tibet, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.